Shamburg News · 8-K filed Nov 12, 2026, 4:45 PM EST

Sutro Biopharma Reports Third Quarter 2026 Financial Results and Business Highlights

STRO · SUTRO BIOPHARMA, INC.

  • Earnings
  • Materiality: high

Sutro Biopharma reported unaudited results for the quarter ended September 30, 2026, with revenue of $9.1 million compared with $9.7 million a year earlier and a net loss of $31.5 million, or $1.90 per share, versus $56.9 million, or $6.66 per share, in the prior-year quarter. Cash, cash equivalents and marketable securities were $142.2 million as of September 30, 2026, which the company expects to support operations into the first half of 2028. The press release also described pipeline progress, including first patient dosing of STRO-006 and a $10 million Astellas milestone payment received in October 2026.

Read the filing on EDGAR ↗

Source: SEC EDGAR, Form 8-K, Items 2.02, 9.01, accession 0001193125-26-458641.

Written from the filing by Shamburg Markets. Figures are as reported by the company.